GENE ONLINE|News &
Opinion
Blog

2022-06-23| Special

BIO 2022: Challenges in Developing Cell and Gene Therapies

by GeneOnline
Share To

In recent years, cell and gene therapies (CGTs) are at the forefront of modern advancements in the biopharma industry. It is expected that CGTs can offer a massive paradigm shift from current treatment options and hold the potential to revolutionize the way we treat diseases including cancers, genetic diseases and infectious diseases.

At the annual BIO International Convention (BIO 2022) in San Diego, CA, a breakout session titled “Therapeutic Cell and Gene Therapy Modalities - Business and Manufacturing Strategies Impacting the Decision to Develop One Therapy Type vs. Another” was held on June 14. Representatives from biopharmaceutical and technology companies focused on developing cell and gene therapy modalities not only shared their achievements accomplished in this field, but also expressed their view on challenges faced when developing novel treatment modalities and issues involving business and manufacturing strategies. The panel consisted of three speakers: 

It's free! Log in now to read

LATEST
Preventive Medicine for Neurodegeneration on the Rise: New Breakthrough in Routine Blood Testing for Alzheimer’s Disease
2024-05-20
Discrimination Leads to Rapid Aging, Science Shows the Detrimental Effects of this Act
2024-05-17
A New Study has Linked Treatment Resistant Depression to Body Mass Index
2024-05-16
AI Reveals Sex-Related Brain Differences and Precision Medicine Potential
2024-05-16
The EU Sustainability Directive’s Influence on Pharmaceutical Supply Chains
2024-05-15
New UC Berkeley Study Challenges Traditional Views on Lactate and Carbohydrate Metabolism
2024-05-15
First Person to Receive Transplanted Pig Kidney has Died
2024-05-13
EVENT
Scroll to Top